Compare Match Group Inc (MTCH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Match Group Inc trades at $42.39 (market cap $9.72B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Match Group Inc is the larger of the two by market cap, and Match Group Inc pays a 1.89% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MTCH | TVTX | |
|---|---|---|
Market Cap | $9.72B | $4.88B |
Volume | 4,140,020 | 1,668,577 |
Sector | Media | Health |
52-Week High | $44.40 | $67.52 |
52-Week Low | $28.90 | $26.79 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $12.69B | $5.01B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $42.36, up 2.02% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with support at $41 and resistance at $43. Recent earnings beat expectations in Q2 2026, and the company maintains strong profitability with a 74.8% gross margin. Positive sentiment is driven by Tinder's turnaround and Hinge's growth, with analyst consensus leaning Buy.
Outlook is cautiously optimistic with revenue stability and margin expansion potential. Key risks include high debt levels and competitive pressures. The absence of Sell ratings and institutional accumulation support a favorable medium-term view, but investors should monitor execution on product innovations and user growth.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
